Aiforia is a company that has generated considerable discussion among investors.
While some believe in its significant growth potential, the risks involved are also noteworthy.
I definitely recommend reading this excellent and comprehensive analysis of the company. 
Aiforia has become the market leader in clinical pathology image recognition, winning the majority of new contracts in the market in recent years. During the same period, the regulatory bottleneck that has been in the way of expanding the company’s product portfolio has opened, enabling expansion in existing customers and larger deal sizes in future tenders. Although the trade war that has started will have a potentially milder negative impact on the market, we expect Aiforia’s revenue growth to be on a strong footing in the near future. Supported by these drivers, we see the risk/reward of the stock at an attractive level. We revise our target price to EUR 4.2 (was EUR 4.4) and reiterate our Accumulate recommendation.
